Chronic Myeloid Leukemia News and Research

RSS

Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

BioSante Pharmaceuticals, Inc. today announced that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine for the treatment of prostate cancer has been lifted by FDA.

7 Jun 2011

Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer

Customizing targeted therapies to each tumor's molecular characteristics, instead of a one-size-fits-all approach by tumor type, may be more effective for some types of cancer, according to research conducted by The University of Texas MD Anderson Cancer Center.

4 Jun 2011

ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011

ARIAD Pharmaceuticals, Inc. today announced initial clinical findings on ponatinib in patients with advanced acute myeloid leukemia (AML).

3 Jun 2011

Leukemia protein plays a role in Alzheimer's disease

After decades of studying the pathological process that wipes out large volumes of memory, scientists at The Feinstein Institute for Medical Research discovered a molecule called c-Abl that has a known role in leukemia also has a hand in Alzheimer's disease.

25 May 2011

New combination therapy eradicates acute lymphoblastic leukemia in children, older adults

In a significant breakthrough, investigators at Weill Cornell Medical College and the University of California, San Francisco, have been able to overcome resistance of a form of leukemia to targeted therapy, demonstrating complete eradication of the cancer in cell and animal studies.

25 May 2011

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb Company, a leading global BioPharma company in oncology, today announced that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 3-7.

21 May 2011

New study sheds light on origins of myeloid leukemia

A new study by the NYU Cancer Institute, an NCI-designated cancer center, sheds light on the origins of myeloid leukemia, a type of blood cancer that affects children and adults.

13 May 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

11 May 2011

CytRx reports $6.3 million net loss for first quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months ended March 31, 2011, and provided a business update.

5 May 2011

Clontech releases iDimerize inducible dimerization systems

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the release of the iDimerize inducible dimerization systems. Based on the widely used ARGENT™ technology developed by ARIAD Pharmaceuticals, Inc., the iDimerize systems enable precise, real-time control of protein-protein interactions using specific cell-permeable chemical ligands, called dimerizers.

20 Apr 2011

Novel drug holds potential against resistant chronic myeloid leukemia

A study from Tufts Medical Center researchers published today finds that a novel drug shows promise for treating leukemia patients who have few other options because their disease has developed resistance to standard treatment.

12 Apr 2011

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on ponatinib, its investigational pan-BCR-ABL inhibitor, showing potent inhibition of all four members of the fibroblast growth factor receptor (FGFR) family of tyrosine kinases that are abnormally expressed in multiple cancers. ARIAD scientists are presenting the data this morning at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

5 Apr 2011

Scientists identify new treatment target for squamous cell lung cancer

Scientists at the Dana Farber Cancer Institute have identified a mutation in the DDR2 gene that may indicate which patients with squamous cell lung cancer will respond to dasatinib.

4 Apr 2011

Positive outcomes from imatinib trial in both older and younger patients with CML

While the median age at diagnosis for chronic myeloid leukemia is over 60 years old and incidence increases dramatically with age,limited data are available about the long-term outcome for older patients treated with imatinib, the standard first-line therapy used to treat CML.

31 Mar 2011

Cephalon intends to make takeover bid for ChemGenex

Cephalon, Inc. and ChemGenex Pharmaceuticals Limited today jointly announced that Cephalon's wholly-owned subsidiary, Cephalon CXS Holdings Pty Ltd, intends to make a takeover bid for ChemGenex.

29 Mar 2011

Cancer drug Gleevec may hold promise against scleroderma: Study

A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec- (imatinib) could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.

28 Mar 2011

MolecularMD and ARIAD collaborate to develop and commercialize CML, ALL diagnostic test

ARIAD Pharmaceuticals, Inc. and MolecularMD Corporation today announced an exclusive collaboration agreement in which MolecularMD will develop and commercialize a companion diagnostic test to identify the T315I mutation of the BCR-ABL gene in patients with chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia.

28 Mar 2011

KaloBios commences KB004 Phase 1 trial in patients with leukemia

KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced treatment of the first patient in a Phase 1 clinical trial of KB004, its first-in-class Humaneered™ monoclonal antibody, in EphA3-expressing hematologic malignancies.

24 Mar 2011

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the initiation of a Phase I/II clinical trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia.

23 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011